LenioBio Reaches Industrial-Scale with its High-Yield Eukaryotic Platform for Cell-Free Protein Synthesis
PR96332
DUSSELDORF, Germany, June 8, 2022/PRNewswire=KYODO JBN/--
LenioBio GmbH today announced it had achieved a key milestone for the company
with the successful linear scaling of its cell-free protein synthesis (CFPS)
platform, ALiCE(R), to an industrial scale.
Through a series of breakthrough developments, ALiCE(R) can now be used to
produce up to 3g/litre of complex, functional proteins in reaction volumes of
up to 10 litres, without requiring extensive process development and
optimization, and without compromising on protein yield. This offers a
significant step forward in eukaryotic protein expression.
The key differentiator of ALiCE(R) at scale, compared to other cell-free
expression systems, is its unique achievement in keeping the protein production
machinery of the living cell intact: active energy supply and everything needed
for protein folding, disulfide bonding, and glycosylation.
CFPS systems offer a number of benefits over cell-based protein alternatives,
including shorter protein production time (hours vs. months), and the ability
to produce proteins at levels usually toxic to living cells. However, the
widespread adoption of CFPS in industrial protein manufacture has been hindered
by a lack of systems that can reliably operate at scale.
CEO Remberto Martis said: "We are extremely excited about the response received
from the industry and collaboration partners in reaching this important
milestone. The scaling of LenioBio's CFPS system, combined with its ability to
produce complex proteins with eukaryotic post-translational modifications,
opens the door to many applications beyond research and development."
To accommodate future demands for larger volumes of their cell-free lysate, the
company is scaling the technology further to 100L production capacity.
Scaling of the technology is one outcome of the two-year PEPPER project
(881025), funded by the EU Horizon 2020 program, which was successfully
completed in February 2022. LenioBio will be exhibiting within the European
Innovation Council Pavilion (Hall C, booth #1911) at the 2022 BIO International
Convention, June 13-16. The team will be happy to discuss this and other recent
developments at the company.
About LenioBio
LenioBio is a protein expression platform company committed to advancing
transformative technology for the discovery, development, and large-scale
production of proteins, unconstrained by the limitations of the cell.
LenioBio was established as a legal entity in Germany in September 2016, with
offices in Dusseldorf and R&D and production labs in Aachen.
For more information, visit: https://www.leniobio.com/ and follow LenioBio on
LinkedIn: https://www.linkedin.com/company/leniobio-gmbh/
Photo: https://mma.prnewswire.com/media/1832436/LenioBio.jpg
Logo: https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg
Source: LenioBio GmbH
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。